Patents by Inventor Yafei Jin
Yafei Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132371Abstract: A positive electrode material, a preparation method therefor, and an application thereof are disclosed. The cathode material is composed of secondary particles agglomerated by primary particles; wherein individual secondary particle contains an inner core structure, a middle layer, and a shell layer, in this order, along a direction from a center to a surface of the secondary particle; wherein the middle layer is distributed in a circular ring shape; and wherein the secondary particle has a structure of close packing of an inner core structure, loose and porous middle layer, and close packing of the shell layer.Type: ApplicationFiled: December 29, 2023Publication date: April 25, 2024Applicant: BEIJING EASPRING MATERIAL TECHNOLOGY CO., LTD.Inventors: Hang ZHANG, Yafei LIU, Yuqiang JIN, Xuequan ZHANG, Yanbin CHEN
-
Publication number: 20140357673Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.Type: ApplicationFiled: July 31, 2014Publication date: December 4, 2014Inventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey William Perry, Roderick Joseph Sorenson, Mary Xuan Dziem O'Riordan, Yafei Jin
-
Patent number: 8809377Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g.Type: GrantFiled: September 23, 2011Date of Patent: August 19, 2014Assignee: The Regents of the University of MichiganInventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey W. Perry, Roderick J. Sorenson, Mary X. O'Riordan, Yafei Jin
-
Publication number: 20120077806Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey W. Perry, Roderick J. Sorenson, Mary X. O'Riordan, Yafei Jin
-
Patent number: 7884099Abstract: The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the inventive compounds is that both the rifamycin and quinolone antibacterial pharmacophores are co-delivered with matched pharmacokinetics to the targeted pathogens of interests. Delivery of multiple antibacterial pharmacophores simultaneously to the targeted pathogens has the maximum chance of achieving synergy and minimizing the development of resistance to the antibiotics given.Type: GrantFiled: November 12, 2008Date of Patent: February 8, 2011Assignee: Cumbre IP Ventures, L.P.Inventors: Charles Z. Ding, Yafei Jin, Keith Combrink, In Ho Kim
-
Patent number: 7678791Abstract: Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.Type: GrantFiled: July 12, 2007Date of Patent: March 16, 2010Assignee: Cumbre IP Ventures, L.P.Inventors: Charles Z. Ding, In Ho Kim, Jiancheng Wang, Zhenkun Ma, Yafei Jin, Keith D. Combrink, Genliang Lu, A. Simon Lynch
-
Publication number: 20090143373Abstract: The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the inventive compounds is that both the rifamycin and quinolone antibacterial pharmacophores are co-delivered with matched pharmacokinetics to the targeted pathogens of interests. Delivery of multiple antibacterial pharmacophores simultaneously to the targeted pathogens has the maximum chance of achieving synergy and minimizing the development of resistance to the antibiotics given.Type: ApplicationFiled: November 12, 2008Publication date: June 4, 2009Applicant: Cumbre Pharmaceuticals Inc.Inventors: Charles Z. Ding, Yafei Jin, Keith Combrink, In Ho Kim
-
Patent number: 7432242Abstract: The present invention relates to novel inhibitors of G-protein signaling. In particular, the present invention provides peptide inhibitors of G protein signaling proteins and methods of using such inhibitors to modulate physiological effects of G protein signaling. The present invention thus provides novel drug targets for a variety of pathologies mediated by defects in G-protein signaling.Type: GrantFiled: February 13, 2003Date of Patent: October 7, 2008Assignee: The Regents of the University of MichiganInventors: Henry I. Mosberg, Richard R. Neubig, Yafei Jin, Hauiling Zhong, Roger Sunahara
-
Publication number: 20080139577Abstract: Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.Type: ApplicationFiled: July 12, 2007Publication date: June 12, 2008Applicant: Cumbre Pharmaceuticals Inc.Inventors: Charles Z. Ding, In Ho Kim, Jiancheng Wang, Zhenkun Ma, Yafei Jin, Keith D. Combrink, Genliang Lu, A. Simon Lynch
-
Patent number: 7247634Abstract: Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.Type: GrantFiled: January 12, 2005Date of Patent: July 24, 2007Assignee: Cumbre Pharmaceuticals Inc.Inventors: Zhenkun Ma, Yafei Jin, Jing Li, Charles Z. Ding, Keith P. Minor, Jamie C. Longgood, In Ho Kim, Susan Harran, Keith Combrink, Timothy W. Morris
-
Patent number: 7238694Abstract: The present invention relates to rifamycin 3-iminomethylenyl (—CH?N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH?N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.Type: GrantFiled: January 12, 2005Date of Patent: July 3, 2007Assignee: Cumbre Pharmaceuticals, Inc.Inventors: Charles Z. Ding, Yafei Jin, Jamie C. Longgood, Zhenkun Ma, Jing Li, In Ho Kim, Keith P. Minor, Susan Harran
-
Patent number: 7229996Abstract: Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.Type: GrantFiled: July 21, 2005Date of Patent: June 12, 2007Assignee: Cumbre Pharmaceuticals Inc.Inventors: Zhenkun Ma, Jing Li, Susan Harran, Yong He, Keith P. Minor, In Ho Kim, Charles Z. Ding, Jamie C. Longgood, Yafei Jin, Keith D. Combrink
-
Patent number: 7226931Abstract: Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or its salts, hydrates or prodrugs thereof; wherein a preferred R1 comprises hydrogen or acetyl and a prefered R2 comprises hydrogen, methyl or other lower alkyls; wherein asterik (*) denotes the carbon bearing the chiral center, wherein absolute configuration is assigned as R or S. Methods of preparation of the aforementioned rifamycin derivatives are also described. The compounds exhibit antimicrobial activities, including activities against drug-resistant microorganisms.Type: GrantFiled: July 21, 2005Date of Patent: June 5, 2007Assignee: Cumbre Pharmaceuticals Inc.Inventors: Charles Z. Ding, Zhenkun Ma, Jing Li, Susan Harran, Yong He, Keith P. Minor, In Ho Kim, Jamie C. Longgood, Yafei Jin, Keith D. Combrink
-
Publication number: 20060019986Abstract: Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or its salts, hydrates or prodrugs thereof; wherein a preferred R1 comprises hydrogen or acetyl and a prefered R2 comprises hydrogen, methyl or other lower alkyls; wherein asterik (*) denotes the carbon bearing the chiral center, wherein absolute configuration is assigned as R or S. Methods of preparation of the aforementioned rifamycin derivatives are also described. The compounds exhibit antimicrobial activities, including activities against drug-resistant microorganisms.Type: ApplicationFiled: July 21, 2005Publication date: January 26, 2006Applicant: Cumbre Inc.Inventors: Charles Ding, Zhenkun Ma, Jing Li, Susan Harran, Yong He, Keith Minor, In Kim, Jamie Longgood, Yafei Jin, Keith Combrink
-
Publication number: 20060019985Abstract: Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.Type: ApplicationFiled: July 21, 2005Publication date: January 26, 2006Applicant: Cumbre Inc.Inventors: Zhenkun Ma, Jing Li, Susan Harran, Yong He, Keith Minor, In Kim, Charles Ding, Jamie Longgood, Yafei Jin, Keith Combrink
-
Publication number: 20050261262Abstract: Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.Type: ApplicationFiled: January 12, 2005Publication date: November 24, 2005Applicant: Cumbre Inc.Inventors: Zhenkun Ma, Yafei Jin, Jing Li, Charles Ding, Keith Minor, Jamie Longgood, In Kim, Susan Harran, Keith Combrink, Timothy Morris
-
Publication number: 20050209210Abstract: The present invention relates to rifamycin 3-iminomethylenyl (—CH?N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH?N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.Type: ApplicationFiled: January 12, 2005Publication date: September 22, 2005Applicant: Cumbre Inc.Inventors: Charles Ding, Yafei Jin, Jamie Longgood, Zhenkun Ma, Jing Li, In Kim, Keith Minor, Susan Harran
-
Publication number: 20050118624Abstract: Fluorescent probes that have binding affinity to ribosomes. The fluorescent probes are useful tools for identifying small molecules that bind to the 50S or 30S subunits of the bacterial and other ribosomes and serve as novel ribosome inhibitors. These probes are also useful for determining the interactions between a specific ligand and the ribosome.Type: ApplicationFiled: September 30, 2004Publication date: June 2, 2005Applicant: Cumbre Inc.Inventors: Zhenkun Ma, Jing Li, In Kim, Yafei Jin, Anthony Lynch, Eric Roche, Doug Beeman
-
Publication number: 20040053821Abstract: The present invention relates to novel inhibitors of G-protein signaling. In particular, the present invention provides peptide inhibitors of G protein signaling proteins and methods of using such inhibitors to modulate physiological effects of G protein signaling. The present invention thus provides novel drug targets for a variety of pathologies mediated by defects in G-protein signaling.Type: ApplicationFiled: February 13, 2003Publication date: March 18, 2004Applicant: The Regents of the University of MichiganInventors: Henry I. Mosberg, Richard R. Neubig, Yafei Jin, Hauiling Zhong, Roger Sunahara